Zielhuis Sander W, Nijsen J Frank W, Seppenwoolde Jan-Henry, Bakker Chris J G, Krijger Gerard C, Dullens Hub F J, Zonnenberg Bernard A, van Rijk Peter P, Hennink Wim E, van het Schip Alfred D
Department of Nuclear Medicine, University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Biomaterials. 2007 Nov;28(31):4591-9. doi: 10.1016/j.biomaterials.2007.07.012. Epub 2007 Jul 25.
The aim of this study was to get insight into the toxic effects of holmium-166-loaded poly(L-lactic acid) microspheres (Ho-PLLA-MS) which have very interesting features for treatment of liver malignancies. Acute, mid- and long-term effects were studied in healthy Wistar rats by evaluating clinical, biochemical and tissue response. Rats were divided into four treatment groups: sham, decayed neutron-irradiated Ho-PLLA-MS, non-irradiated Ho-PLLA-MS and PLLA-MS. After implantation of the microspheres into the liver of the rats, the animals were monitored (body weight, temperature and liver enzymes) for a period of 14-18 months. Some of the rats that received previously neutron-irradiated Ho-PLLA-MS were periodically scanned with magnetic resonance imaging (MRI) to see if holmium was released from the microspheres. After sacrifice, the liver tissue was histologically evaluated. Bone tissue was subjected to neutron-activation analysis in order to examine whether accumulation of released holmium in the bone had occurred. No measurable clinical and biochemical toxic effects were observed in any of the treatment groups. Furthermore, histological analyses of liver tissue samples only showed signs of a slight chronic inflammation and no significant differences in the tissue reaction between rats of the different treatment groups could be observed. The non-irradiated PLLA-MS and Ho-PLLA-MS stayed intact during the study. In contrast, 14 months after administration, the neutron-irradiated Ho-PLLA-MS was not completely spherical anymore, indicating that degradation had started. However, the holmium loading had not been released as was illustrated with MRI and affirmed by neutron-activation analysis of bone tissue. In conclusion, neutron-irradiated Ho-PLLA-MS does not provoke any toxic reaction and can be applied safely in vivo.
本研究的目的是深入了解负载钬 - 166的聚(L - 乳酸)微球(Ho - PLLA - MS)的毒性作用,该微球在治疗肝脏恶性肿瘤方面具有非常有趣的特性。通过评估临床、生化和组织反应,对健康的Wistar大鼠进行急性、中期和长期影响的研究。大鼠被分为四个治疗组:假手术组、经衰变中子辐照的Ho - PLLA - MS组、未辐照的Ho - PLLA - MS组和PLLA - MS组。将微球植入大鼠肝脏后,对动物进行为期14 - 18个月的监测(体重、体温和肝酶)。对一些先前接受过中子辐照的Ho - PLLA - MS的大鼠定期进行磁共振成像(MRI)扫描,以观察钬是否从微球中释放出来。处死动物后,对肝脏组织进行组织学评估。对骨组织进行中子活化分析,以检查释放的钬是否在骨中积累。在任何治疗组中均未观察到可测量的临床和生化毒性作用。此外,肝脏组织样本的组织学分析仅显示出轻微慢性炎症的迹象,不同治疗组大鼠之间的组织反应未观察到显著差异。在研究过程中,未辐照的PLLA - MS和Ho - PLLA - MS保持完整。相比之下,给药14个月后,经中子辐照的Ho - PLLA - MS不再完全呈球形,表明已经开始降解。然而,如MRI所示且经骨组织的中子活化分析证实,钬负载并未释放。总之,经中子辐照的Ho - PLLA - MS不会引发任何毒性反应,可在体内安全应用。